Forecasting and prevention of complication of menopausal hormonal therapy
In modern conditions, the peak of professional activity of many women falls precisely during the period of perimenopause. Therefore, maintaining physical fitness, beauty, health, sexuality, femininity, learning ability, self-improvement and interest in life is very important during this period. Menopausal hormone therapy (MHT) is prescribed for the prevention and elimination of menopausal disorders. It is very important to differentiate the selection of IHT, taking into account the state of health of the woman and the study of concomitant pathology, as well as the modes of its appointment. An individualized approach to the administration of MHT will help to maximize its therapeutic and prophylactic potential, reducing the number of adverse reactions and complications. The aim is to examine the relationship between anamnestic data (obstetric and gynecological and somatic status) and the risk of complications from menopausal hormone therapy. The authors conducted a survey on a specially designed questionnaire of 178 perimenopausal women: had some complications on the background of its use and 80 women of the same age who had no complications from MHT — the control group. During the study, the chances of the occurrence of a particular pathology in women were calculated on the background of taking MHT in the presence of various diseases. It was found that in patients with a history of PMS, DMZ, migraine, unstable blood pressure, overweight, gynecological diseases, namely inflammatory diseases, uterine fibroids, endometriosis, varicose veins, swelling, transmitted diseases the risk of developing complications from MHT is much higher than that in healthy women, which allows them to be put at risk. These complications can be minimized by choosing the optimal treatment regimen, and the benefits of using it can be maximized by taking into account the relationships found. Taking into account the identified links between the studied factors will prevent complications from the use of MHT in each individual woman at the stage of MHT selection and will allow to isolate such patients in the risk group of development or will allow to predict the occurrence of one or another disease depending on the presence of a disease.
2. Kaminskyi, V. V., Antypkin, Yu. H., & Tatarchuk, T. F. (2017). Zberezhennia yakosti zhyttia ta sotsialnoi aktyvnosti zhinok v postreproduktyvnomu periodi [Preserving the quality of life and social activity of women in the post-productive period]. Reproduktyvna endokrynolohiia – Reproductive endocrinology, 2017, 36 (4), 9–11. doi: http://dx.doi.org/10.18370/2309-4117.2017.36.9-12.
3. Kirilyuk, M. L. (2014). Menopauza: suchasni uyavlennya pro bezpeku ta efektivnist likuvannya [Menopause: current ideas about the safety and efficacy of treatment]. Klinichna endokrinologiya ta endokrinna hirurgiya – Clinical endocrinology and endocrine surgery, 47 (2), 63–75.
4. Lapach, S. N., Chubenko, A. V., & Babich, P. N. (2001). Statisticheskie metody v medikobiologicheskih issledovaniyah s ispolzovaniem Excel [Statistical methods in biomedical research using Excel]. Kiev: Morion. ISBN 966-7632-33-4.
5. Prilepskaya, V. N. (2017). Klimaktericheskij sindrom: innovacii v menopauzalnoj terapii [Menopausal Syndrome: Innovations in Menopausal Therapy], RMZh – Russian Medical Journale, 5, 1–4.
6. Tatarchuk, T. F., Islamova, G. O., & Yefimenko, O. O. (2015). Klimaktericheskij sindrom kak pervoe klinicheskoe proyavlenie perimenopauzy. Reproduktivna endokrinologiya – Reproductive endocrinology, 21 (1), 52–56.
7. Tatarchuk, T. F., Pirogova, V. I., Yefimenko, O. O., Bulavenko, O. V., Antonyan, I. M. & Pilyagina, G. Ya. (2018). Individualizaciya pidhodiv do vedennya paciyentok u period menopauzalnogo perehodu [Individualization of approaches to patient management during menopausal transition]. Reproduktivna endokrinologiya – Reproductive endocrinology, 41 (3), 8–11. doi: http://dx.doi.org/10.18370/2309-4117.2018.41. 8–11.
8. De Villiers, Tobi, & Tatarchuk, T. F. (2016). Nacionalnij konsensus shodo vedennya paciyentok u klimakteriyi [National consensus on the management of patients in menopause]. Zdorove zhenshiny – Woman’s health, 110 (4), 17–27.
9. Arnson, Y., Rozanski, A., Gransar, H., Otaki, Y., Doris, M., Wang, F. … Berman, D. (2017). Hormone replacement therapy is associated with less coronary atherosclerosis and lower mortality. Journal of the American College of Cardiology, 69 (11), 1408. doi: 10.1016/S0735-1097(17)34797-6.
10. Baber, R. J., Panay, N., Fenton, A., Cardozo, L., Castelo-Branco, C., Davis, S. R. ... Vujovic, S. Z. (2016). IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 19(2), 109–150. doi: 10.3109/13697137.2015.1129166.
11. Birkhaeuse, M. & Genazzani, A. R. (Eds.) (2018). Pre-Menopause, Menopause and Beyond. Springer International Publishing. ISBN 978-3-319-63540-8.
12. Bolton, J. L. (2016). Menopausal hormone therapy, age, and chronic diseases: perspectives on statistical trends. Chem. Res. Toxicol., 29 (10), 1583–1590. doi: 10.1021/acs.chemrestox.6b00272.
13. Borrelli, F., & Edzard, E. (2010). Alternative and complementary therapies for the menopause. Maturitas, 66(4), 333–343. doi: 10.1016/j.maturitas.2010.05.010.
14. de Villiers, T. J., Pines, A. N., Panay, M., Gambacciani, D. F., Archer, R. J., Baber, S. R. … Sturdee, D. W. (2013). Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Сlimacteric, 16(3), 316–337. doi: 10.3109/13697137.2013.795683.
15. Hickey, M., Jane, E., & Davison, S. L. (2012). Hormone replacement therapy. BMJ, 344. doi: https://doi.org/10.1136/bmj.e763.
16. Long, M. E., Faubion, S. S., MacLaughlin, K. L., Pruthi, S., & Casey, P. M. (2015). Contraception and Hormonal Management in the Perimenopause. J. Women’s health, 24 (1), 3–10. doi:10.1089/jwh.2013.4544.
17. Palacios, S., Stevenson, J. C., Schaudig, K., Lukasiewicz, M., & Graziottin, A. (2019). Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. Womens Health (Lond), 15. doi: 10.1177/1745506519864009.
18. Papadakis, G. E., Hans, D., Rodriguez, E. G., Vollenweider, P., Waeber, G., Marques-Vidal, P., Lamy, O. (2018). Menopausal hormone therapy is associated with reduced total and visceral adiposity: The osteolaus cohort. The Journal of Clinical Endocrinology & Metabolism, 103 (5), 1948–1957. doi: 10.1210/jc.2017-02449.
19. Pongsatha, S., Morakot, N., & Chaovisitsaree, S. (2012). Sexual in menopausal women comparing perimenopausal and postmenopausal women. J. Med. Assoc. Thai., 95 (12), 1489–1494. PMID: 23390777.
20. Richards M., Rubinow D., Daly R., & Schmidt, P. (2006). Premenstrual symptoms and perimenopausal depression. Am. J. Psychiatry, 163 (10), 133–137. doi: 10.1176/appi.ajp.163.1.133.
This work is licensed under a Creative Commons Attribution 4.0 International License.